Shanghai Pharma Biotherapeutics USA Inc.
2 clinical trials · Sponsor
◉ Watch Shanghai Pharma Biotherapeutics USA Inc.
| Record | Firm | Date |
|---|---|---|
| Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas (NCT05580588) | Shanghai Pharma Biotherapeutics USA Inc. | 2023-08-31 |
| Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis (NCT05019742) | Shanghai Pharma Biotherapeutics USA Inc. | 2022-03-21 |
Track Shanghai Pharma Biotherapeutics USA Inc. automatically
Every clearance here is in the API, with alerts when new ones post.